CLDN News Alert Celladon Corp (CLDN) 12.19 11/13/2014 17:29:

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 6:29 PM

Celladon Corp (CLDN) 12.19 $CLDN

Celladon Net loss of $8.35M
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:18AM CST

CLDN: 12.19 (+0.12)

Celladon Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Nov 12, 5:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended September 30, 2014 and recent corporate highlights and updates.
CLDN: 12.19 (+0.12)

Celladon Corporation to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Fri Nov 07, 3:05PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 12.19 (+0.12)

Celladon Corporation to Present at Credit Suisse Healthcare Investor Conference
GlobeNewswire - Wed Nov 05, 3:38PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 12.19 (+0.12)

Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for MYDICAR(R)
GlobeNewswire - Mon Nov 03, 5:00AM CST
-- Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR(R)
CLDN: 12.19 (+0.12)

Larsen MacColl Partners, LP Divests A&S Services Group, LLC
Business Wire - Fri Oct 31, 6:00AM CDT
Larsen MacColl Partners, LP ("LMP"

, announced today that on October 24, 2014 it sold its portfolio company, A&S Services Group, LLC and affiliates (collectively, "A&S"

, to Celadon Group, Inc. The purchase price was $55 million and LMP will realize a 24x multiple of its invested capital from the sale.
CLDN: 12.19 (+0.12)

Celadon Group Reports September Quarter Results and Declares Dividend
PR Newswire - Wed Oct 29, 4:20PM CDT
Celadon Group Inc. (NYSE : CGI) today reported its financial and operating results for the three months ended September 30, 2014, the first quarter of the Company's fiscal year ending June 30, 2015.
CLDN: 12.19 (+0.12), CGI: 21.80 (+0.04)

Celadon Group Acquires A&S Services Group, LLC
PR Newswire - Mon Oct 27, 1:27PM CDT
Celadon Group, Inc. (NYSE: CGI) "Celadon", one of North America's premier transportation and logistics companies, today announced the acquisition of A&S Services Group, LLC ("A&S"

. A&S is a leading regional for-hire and dedicated truckload carrier based in New Freedom, PA. A&S's fleet operations provide dry van transportation services almost exclusively and principally serve the Mid-Atlantic and Northeast regions. A&S is also a major supplier of logistics, warehousing and distribution services in the area.
CLDN: 12.19 (+0.12), CGI: 21.80 (+0.04)

Celladon Corporation Announces Publication of Data From Its Stem Cell Factor Gene Therapy Program in Circulation Heart Failure
GlobeNewswire - Mon Oct 27, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a biotechnology industry leader in the field of cardiovascular gene therapy, today announced together with researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, the results of pre-clinical work on the membrane-bound form of the Stem Cell Factor (mSCF) gene therapy product candidate in the September 2014 online issue of Circulation Heart Failure. The paper is entitled "Stem Cell Factor Gene Therapy Improves Cardiac Function after Myocardial Infarction in Swine".
CLDN: 12.19 (+0.12)

Celadon Group Announces Executive Team Changes
PR Newswire - Tue Oct 21, 3:57PM CDT
Celadon Group, Inc. (NYSE: CGI) today announced changes to its executive team. The changes are effective immediately.
CLDN: 12.19 (+0.12), CGI: 21.80 (+0.04)

Celadon Group Announces Dates for Earnings Release and Conference Call and for Upcoming Investor Conferences
PR Newswire - Fri Oct 03, 9:19AM CDT
Celadon Group Inc. (NYSE: CGI) will release its fiscal 2015 first quarter results on Wednesday, October 29 after the close of the market. A conference call to discuss the first quarter results will be held Thursday, October 30 at 11:00 a.m. Eastern Time.
CLDN: 12.19 (+0.12), CGI: 21.80 (+0.04)

Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 11.51 (+0.17), DNDN: 0.13 (-0.03), VNDA: 12.17 (-0.65), OSIR: 13.30 (-0.20), CLDN: 12.19 (+0.12), GALE: 1.88 (-0.04), CTIC: 2.15 (-0.03), OTIC: 23.69 (+0.01)

Celladon to Present at the 2014 Stem Cell Meeting on the Mesa
GlobeNewswire - Wed Oct 01, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
CLDN: 12.19 (+0.12)

Celladon Corporation Appoints Scott Garrett Vice President, Commercial Planning
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), CLDN: 12.19 (+0.12)

Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
PFE: 30.42 (unch), PTN: 0.75 (-0.02), CLDN: 12.19 (+0.12), AMGN: 160.85 (-1.08), NVS: 94.38 (+1.72)

Nasdaq stocks posting largest percentage increases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LOXO: 11.51 (+0.17), ACET: 21.29 (-0.27), MAGS: 4.57 (+0.08), CLDN: 12.19 (+0.12)

Why You Shouldn't Bet Against Celladon Corporation (CLDN) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:57AM CDT
Celladon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
CLDN: 12.19 (+0.12)

Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose over 11% on the day.
CBPO: 66.35 (-2.38), CBM: 23.36 (-0.66), GILD: 104.20 (-2.70), CLDN: 12.19 (+0.12)

5 Stocks Moving on Unusual Volume
at The Street - Tue Aug 19, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
DRTX: 23.75 (-0.14), MVNR: 14.15 (-0.31), WBMD: 39.45 (-0.74), CRTO: 38.20 (+0.92), CLDN: 12.19 (+0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CACI Hits $50K Milestone in Service Dog Program

Ice Blocking for a Noble Cause Last I checked, mixing the adrenaline of ice hockey with the grit of veteran support isn't your typical skate on thin ice. But CACI International Inc (NYSE:CACI), with their Good Dogs for Great Americans program, is doing just that. They're taking every blocked shot by the Washington Capitals and turning it into a stepping stone for veterans...

Jacquie Lawson's Advent Calendar Delights Fans for 17th Year

A Festive Tradition with a Twist The Jacquie Lawson Advent calendar is back for its 17th season, and it's no ho-hum affair. This time, the scene is set against the breathtaking backdrop of England's Lake District. If you've been yearning for a bit of that classic literary and natural charm, this is your ticket—minus the airfare. The calendar isn't just a countdown; it's...

LifeStance Expands Access to Esketamine, TMS

LifeStance Health's Treatment Innovations Today, the spotlight is on LifeStance Health, as they're making waves with their treatment approaches for those battling stubborn, treatment-resistant depression. This isn't your run-of-the-mill attempt at tackling the beast—that familiar indifference masked as hope. No, this time around, they’re swinging with Esketamine and...

OCI Cleared to Merge with Orascom, Sets Delisting Date

OCI N.V. has hit a milestone. The shareholders have given the green light to merge with Orascom Construction PLC. This move is fleshed out with an updated roadmap that sharp-eyed investors need to watch closely. The company's shares will no longer be trading on Euronext Amsterdam by late November 2026, contingent on regulatory nods and other variables swirling in the...

Sentral Expands: Fort Lauderdale & San Diego Additions

Sentral's Strategic Leap into New Markets Ever heard of a company spreading its wings like wildfire? That’s Sentral for you, crashing into Fort Lauderdale and pushing deeper roots in San Diego. We’re not talking minor plays here—these two fresh additions make Sentral a resident-giant stretched across 22 markets. Seems like they’re on a mission to ink their mark...

Lecanemab's New Data: What Investors Should Monitor

Lecanemab: A Bold Step in Alzheimer's Treatment? Investors eyeing the biotech sector should pay close attention to the upcoming CTAD conference in 2026, where BioArctic AB's partner, Eisai, is set to present fresh data on lecanemab (Leqembi®). This isn't just another pharma front-page story—this is about potential breakthroughs in Alzheimer's treatment that's caught...

WhiteFiber's Q3 2026 Call: Key Insights Await Investors

Eyes on WhiteFiber's Upcoming Earnings Call You know the drill—results call season can make or break some days for us investors. WhiteFiber, Inc. (NASDAQ: WYFI) is gearing up for their third-quarter earnings call on November 10, 2026, at 9:00 a.m. Eastern Time. As a player in the AI infrastructure game, expectations ride high. With their networks and data centers...

Kansas City Life's Q3: Earnings Dip, but Growth Ahead

Striking a Balance: Kansas City Life's Q3 They say numbers don’t lie, and Kansas City Life Insurance just shared their latest. This quarter, things weren't all smooth sailing, but there's a silver lining. For Q3 2026, net income clocked in at $1.7 million, or $0.18 per share, down from last year’s $2.8 million, or $0.29 per share. Sure, it wasn't all sunshine and...

Shareholder Stakes at Risk in Major Mergers

Deals in the Spotlight: What's at Stake? Ever wonder if you're getting the short end of the stick while company insiders walk away with the spoils? That's the song and dance investors face with the likes of ADT Inc., Instacart, and MidCap Financial Investment Corporation lately. If you're wearing the shareholder hat, you might want to tune into the noise around these...

Hehe Culture's Timeless Wisdom Explored at Forum

Hehe Forum: Bridging the Past and Present Sometimes, the past isn't just anchor weight, it's a compass guiding us through the murky waters of today. The Hehe Culture Forum's latest gathering in Tiantai County, Zhejiang Province, aimed to unravel just how much ancient wisdom can still steer the course in this fast-changing world. Delegates from 23 nations joined forces,...